Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Immunometabolic reprogramming of macrophages by miR-423-5p-enriched small extracellular vesicles delivered via glucose/ROS-responsive hydrogel for diabetic wound healing.

Chen M., Guo Q., Qin Z., Tang Z., He J., Xiang T.

Laboratory Study on Diabetic Foot, Chronic Wound, Chronic Inflammation, Immune Modulation, published in J Nanobiotechnology (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Nanobiotechnology (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42458558
DOI
10.1186/s12951-026-04685-8

Abstract (original English)

Chronic diabetic wounds remain a formidable clinical challenge due to a self-sustaining immunometabolic dysfunction. The hyperglycemic and pro-oxidative microenvironment locks infiltrating macrophages in a glycolysis-dependent pro-inflammatory state, actively suppressing the phenotypic switch to pro-reparative M2 polarization and severely impairing angiogenesis. Current single-target interventions fail to disrupt this vicious inflammatory-metabolic cycle, underscoring an urgent need for strategies capable of spatiotemporally resetting local immune homeostasis. In this study, the pro-reparative capacity of ADSCs-EVs and UCMSCs-EVs was systematically compared through a panel of in vitro functional assays (proliferation, migration, tube formation, and macrophage polarization) and a diabetic mouse wound model. Small RNA sequencing was employed to identify a key effector miRNA enriched in UCMSCs-EVs, and its target regulatory mechanism was validated through miRNA mimic transfection combined with HDDC3 overexpression rescue experiments. Meanwhile, a glucose/ROS dual-responsive injectable hydrogel (DCH) was constructed from oxidized dextran, carboxymethyl chitosan, and phenylboronic acid-modified hyaluronic acid via physical mixing and dynamic double crosslinking through Schiff-base and boronate ester bonds, enabling the pathology-triggered, on-demand release of EVs. Comparative bioac

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research